Wu et al., 2004 - Google Patents

In vivo electroporation of skeletal muscles increases the efficacy of Japanese encephalitis virus DNA vaccine

Wu et al., 2004

Document ID: 14699417907986789103
Author: Wu C; Lee S; Huang H; Tao M
Publication year: 2004
Publication venue: Vaccine

External Links

Cited by

Snippet

DNA vaccines can induce protective immunity against subsequent viral challenge. However, for some DNA vaccines to be effective when administered intramuscularly, cardiotoxin pretreatment is necessary. In this study, we used the technique of in vivo electroporation to …

Continue reading at www.sciencedirect.com (other versions)

238000004520 electroporation 0 title abstract description 82

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body

Similar Documents

Publication	Publication Date	Title
Wu et al.	2004	In vivo electroporation of skeletal muscles increases the efficacy of Japanese encephalitis virus DNA vaccine
Drabick et al.	2001	Cutaneous transfection and immune responses to intradermal nucleic acid vaccination are significantly enhanced by in vivo electropermeabilization
Selby et al.	2000	Enhancement of DNA vaccine potency by electroporation in vivo
Zucchelli et al.	2000	Enhancing B-and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer
Tollefsen et al.	2002	Improved cellular and humoral immune responses against Mycobacterium tuberculosis antigens after intramuscular DNA immunisation combined with muscle electroporation
INCHAUSPE et al.	1997	Plasmid DNA expressing a secreted or a nonsecreted form of hepatitis C virus nucleocapsid: comparative studies of antibody and T-helper responses following genetic immunization
Aguiar et al.	2001	Enhancement of the immune response in rabbits to a malaria DNA vaccine by immunization with a needle-free jet device
Tacket et al.	1999	Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device
Luxembourg et al.	2007	Electroporation-based DNA immunisation: translation to the clinic
Eo et al.	2001	Immunopotentiation of DNA vaccine against herpes simplex virus via co-delivery of plasmid DNA expressing CCR7 ligands
US6610044B2 (en)	2003-08-26	Method for genetic immunization
Scheerlinck et al.	2001	The immune response to a DNA vaccine can be modulated by co-delivery of cytokine genes using a DNA prime-protein boost strategy
Bachy et al.	2001	Electric pulses increase the immunogenicity of an influenza DNA vaccine injected intramuscularly in the mouse
Haensler et al.	1999	Intradermal DNA immunization by using jet-injectors in mice and monkeys
Zhang et al.	2004	Enhancement of the effectiveness of electroporation-augmented cutaneous DNA vaccination by a particulate adjuvant
Bahadoran et al.	2017	Induction of a robust immune response against avian influenza virus following transdermal inoculation with H5-DNA vaccine formulated in modified dendrimer-based delivery system in mouse model
Zhu et al.	2003	Enhancement of DNA vaccine potency against herpes simplex virus 1 by co-administration of an interleukin-18 expression plasmid as a genetic adjuvant
Kim et al.	2008	Increased in vivo immunological potency of HB-110, a novel therapeutic HBV DNA vaccine, by electroporation
Dobaño et al.	2007	Enhancement of antibody and cellular immune responses to malaria DNA vaccines by in vivo electroporation
Zhao et al.	2006	Anti-HBV immune responses in rhesus macaques elicited by electroporation mediated DNA vaccination
Yoon et al.	2006	Cytokine GM‐CSF genetic adjuvant facilitates prophylactic DNA vaccine against pseudorabies virus through enhanced immune responses
Lodmell et al.	2001	Post-exposure DNA vaccination protects mice against rabies virus
Dayball et al.	2003	Electroporation enables plasmid vaccines to elicit CD8+ T cell responses in the absence of CD4+ T cells
Endmann et al.	2010	Immune response induced by a linear DNA vector: influence of dose, formulation and route of injection
Upadhyay	2006	Enhanced transdermal-immunization with diptheria-toxoid using local hyperthermia